Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)

NCT ID: NCT02543996

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-17

Study Completion Date

2050-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Studies show that rare genetic variants might lead to diseases. Researchers want to collect blood and tissue samples so they can study them and better understand diseases.

Objective:

To collect blood and tissue samples for studies to identify underlying causes of disease.

Eligibility:

People of all ages

Design:

Participants will have blood and/or tissue samples collected.

Samples can be collected at the NIH Clinical Center. Participants doctors can collect the samples and send them to NIH. NIH staff can collect samples off site.

For blood samples, blood is taken from an arm vein using a needle.

Tissue collection may involve:

Buccal smear: Cells are collected by scraping the inside of the cheek with a cotton swab.

Saliva collection: Participants spit into a cup.

Skin biopsy: A special needle takes a very small skin sample.

Surgical waste tissue: If participants have surgery, NIH may receive samples of tissue that

would routinely be removed.

Umbilical cord or cord blood collection: If a participant has a baby, NIH may receive a

small piece of the umbilical cord or blood from the cord once the baby is delivered.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The diversity of human research programs at the National Institutes of Health (NIH) provides a unique opportunity to study different patient populations with monogenetic and undiagnosed diseases with vascular implications. Patient populations with mutations in almost every major signaling pathway related to cardiovascular diseases are actively investigated at the NIH Clinical Center. The purpose of this protocol is to obtain and analyze human biospecimens from affected and unaffected cohorts (as reference biospecimens) to identify genetic etiology and/or underlying disease mechanism(s) in rare genetic vascular/cardiovascular conditions. The collections will consist of biospecimens obtained from participants consented under this protocol and will also provide for the continued storage and analysis of biospecimens previously obtained from NIH Institutional Review Board (IRB)-approved protocols, or from NIH protocols nearing completion. The biospecimens collected under this protocol will include blood (plasma, serum, peripheral blood mononuclear cells (PBMCs)), saliva, buccal mucosa, urine, and skin biopsies. Additional biospecimens collected under other protocols may also be transferred to this protocol, including, tissue and fluid aspirates (cerebrospinal fluid, ascites, etc.), bone marrow, urine, saliva, skin biopsies, surgical tissue waste, malignant and non-malignant tissue samples, and/or other direct derivatives from human tissues (i.e. DNA, RNA, and induced pluripotent stems cells). Post-delivery umbilical cord core blood and cord tissue waste will be collected at the time of delivery under this protocol and/or shared if obtained under other protocols. Biospecimens may also be obtained as shared samples of clinically indicated procedures done inside or outside NIH, provided the subject consents to this protocol.

The primary objective of this protocol is to create a robust resource to support basic and translational research by providing a mechanism for collecting, tracking, storing, dispensing, analyzing, and disposing of laboratory research samples from affected and unaffected cohorts. This research will advance high-quality research in the areas of genetics and personalized medicine.

As this is not a treatment protocol, there is no primary endpoint. Research studies will include, but not be limited to, genomic studies, primary cell isolation and cell culture studies for molecular and biochemical analysis, immunohistological analysis, generation of patient-specific in vitro disease models (i.e. IPSCs), etc. As science is a continuously evolving field, technological advances in research methods will be incorporated into research studies accordingly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Undiagnosed Diseases Cardiovascular Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Sample Collection Laboratory Research Specimens Biospecimen Procurement Rare Diseases Natural History

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Affected or unaffected cohorts (including genetic carriers or non-carriers as

Affected or unaffected cohorts (including genetic carriers or non-carriers as reference biospecimens)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: older than 1 month of age
* Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.
* Unaffected related pregnant women (including spouses/partners) for cord blood and tissue collection (surgical waste) only at the time of delivery.
* Cognitively impaired individuals that are affected
* Cognitively impaired individuals that are related to an affected subject.
* Subjects willing to provide informed consent.

Exclusion Criteria

* Healthy volunteers unable to give informed consent
* Cognitively impaired individuals who are not affected
* Cognitively impaired individuals who are not related to affected subjects.
Minimum Eligible Age

1 Month

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manfred Boehm, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Heart, Lung, and Blood Institute (NHLBI)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

William R Whalen

Role: CONTACT

Phone: (301) 451-3315

Email: [email protected]

Manfred Boehm, M.D.

Role: CONTACT

Phone: (301) 435-7211

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15-H-0190

Identifier Type: -

Identifier Source: secondary_id

150190

Identifier Type: -

Identifier Source: org_study_id